FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
PO:31:175 | Characterizing gastrointestinal involvement in systemic sclerosis: insights from the national systemic sclerosis progression investigation registry of the Italian Society of Rheumatology Francesco Bonomi1, Cosimo Bruni1|2, Silvia Laura Bosello3, Fabio Cacciapaglia4|5, Corrado Campochiaro6, Roberto Caporali7, Veronica Codullo8, Maria Antonietta D'Agostino3, Lorenzo Dagna6, Rossella De Angelis9, Giacomo De Luca6, Dilia Giuggioli10, Serena Guiducci1, Florenzo Iannone4, Francesca Ingegnoli7, Carlomaurizio Montecucco8, Valeria Riccieri11, Clodoveo Ferri10, Marco Matucci Cerinic6, Silvia Bellando Randone1. | 1Scleroderma Unit, Division of Rheumatology AOUC, and Department of Experimental and Clinical Medicine, Uni. of Florence, Firenze, Italy; 2Department of Rheumatology, University Hospital Zurich, University of Zurich Zurigo Switzerland; 3UOC of Rheumatology and Clinical Immunology, Catholic University of the Sacred Heart, Fondazione Policlinico A. Gemelli, Roma, Italy; 4Rheumatology Unit, Department of Emergency Surgery and Organ Transplantations, University of Bari, Bari, Italy; 5Rheumatology Service, F. Miulli General Hospital - Department of Medicine and Surgery, LUM 'G. De Gennaro', Casamassima, Italy; 6Unit of Immunology, Rheumatology, Allergy and Rare Diseases and Inflammation, fibrosis and ageing initiative, UniSR, Milano, Italy; 7Division of Clinical Rheumatology, ASST Pini and Università degli studi di Milano, Milano, Italy; 8Department of Rheumatology, Policlinico San Matteo, Pavia, Italy; 9Rheumatology Unit, Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Ancona, Italy; 10Rheumatology Unit, School of Medicine, University of Modena and Reggio Emilia, Modena, Italy; 11Department of Rheumatology, Sapienza University of Rome, Roma, Italy.
179 -
Adherence to vaccination against SARS-CoV-2 and vaccine safety in patients with IgG4-related disease
1752PDF: 239SUPPLEMENTARY MATERIAL: 89 -
The role of biomechanical factors in ankylosing spondylitis: the patient’s perspective
3433PDF: 1690Supplementary: 464 -
PO:33:190 | Travel distance to tertiary healthcare reflects disease severity and medication access in systemic sclerosis patients: insights from the Italian systemic sclerosis progression investigation registry of the Italian Society of Rheumatology Camilla Teresa Magnanimi1, Enrico De Lorenzis1, Gerlando Natalello1, Fabio Cacciapaglia2, Rossella De Angelis3, Edoardo Cipolletta3, Maria Antonietta D'Agostino1, Veronica Cudullo4, Giacomo De Luca5, Dilia Giuggioli6, Francesca Ingegnoli7, Valeria Riccieri8, Lorenzo Dagna5, Fiorenzo Iannone9, Clodoveo Ferri6, Marco Matucci Cerinic5, Silvia Laura Bosello1. | 1Division of Rheumatology and Clinical Immunology, Catholic University of the Sacred Heart, Fondazione Policlinico Univer, Roma, Italy; 2Department of Medicine and Surgery, LUM University Giuseppe De Gennaro Casamassima e Rheumatology Service Miulli Ge, Bari, Italy; 3Rheumatology Unit - Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Ancona, Italy; 4Department of Rheumatology, Policlinico San Matteo, Pavia, Italy; 5Unit of Immunology, Rheumatology, Allergy and Rare Diseases UnIRAR, IRCCS San Raffaele Scientific Institute, Vita-Salu, Milano, Italy; 6Rheumatology Unit, School of Medicine, University of Modena and Reggio Emilia, Modena, Italy; 7Division of Clinical Rheumatology, ASST Pini, Dept. of Clinical Sciences e Community Health, Research Center for Adult a, Milano, Italy; 8Department of Rheumatology, La Sapienza University of Rome, Roma, Italy; 9Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari, Bari, Italy.
227 -
CO:09:6 | Risk of disease flare during pregnancy and postpartum in inflammatory arthritis: association with therapy discontinuation in the prospective P-RHEUM.it study Dina Zucchi1, Chiara Tani1, Francesca Crisafulli2, Alessia Gatti2, Maria Gerosa3, Cecilia Chighizola3, Melissa Padovan4, Salvatore D'Angelo5, Florenzo Iannone6, Maria Sole Chimenti7, Claudia Lomater8, Francesca Serale9, Veronique Ramoni10, Oscar Epis11, Bernd Raffeiner12, Ariela Hoxha13, Andrea Doria14, Leonardo Santo15, Valentina Canti16, Francesca Bellisai17, Giovanna Cuomo18, on behalf of the P-Rheumit Investigators19, Greta Carrara20, Cristina Di Nicola20, Davide Rozza20, Carlo Alberto Scirè20, Maria Chiara Gerardi11, Angela Tincani2, Laura Andreoli2, Marta Mosca1. | 1Rheumatology Unit, University of Pisa and Azienda Ospedaliero Universitaria Pisana; 2Rheumatology and Clinical Immunology Unit, ASST Spedali Civili, Brescia; 3Clinical Rheumatology Division, ASST Gaetano Pini-CTO and University of Milano; 4Rheumatology Unit, Azienda Ospedaliero-Universitaria S. Anna and University of Ferrara; 5Rheumatology Department of Lucania - San Carlo Hospital, Potenza; 6Rheumatology Unit, DiMePRE-J, University of Bari; 7Department of Systems Medicine, Rheumatology, Allergology and Clinical Immunology, University of Rome-Tor Vergata, Roma; 8Torino Academic Rheumatology Center, A.O. Mauriziano di Torino, University of Torino; 9Rheumatology Unit, ASL CN1 Cuneo; 10Internal Medicine Department, ASST Lodi - Ospedale Maggiore di Lodi; 11Division of Rheumatology, Multispecialist Medical Department, Grande Ospedale Metropolitano Niguarda, Milano; 12Department of Rheumatology, Central Hospital of Bolzano SABES-ASDAA, Bolzano; 13General Medicine and Thrombosis and Hemorrhagic Unit, Department of Medicine, University of Padova; 14Rheumatology Unit, Department of Medicine, University of Padova; 15Rheumatology Unit, Mons. Dimiccoli Hospital, Barletta; 16Division of Immunology, Transplantation and Infectious Diseases, IRCCS Ospedale San Raffaele, Milano; 17Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena; 18Precision Medicine Department, University of Campania L. Vanvitelli, Napoli; 19The Italian Society for Rheumatology; 20Epidemiology Research Unit of the Italian Society for Rheumatology, Milano, Italy
209 -
PO:31:172 | Age and timing of onset of Raynaud's phenomenon and first non-Raynaud sign/symptom as prognostic factors in systemic sclerosis: a retrospective analysis from the systemic sclerosis progression investigation registry of the Italian Society for Rheumatology Silvia Peretti1, Cosimo Bruni2, Silvia Laura Bosello3, Fabio Cacciapaglia4-5, Corrado Campochiaro6-7, Veronica Codullo8, Lorenzo Dagna6-7, Rossella De Angelis9, Giacomo De Luca6-7, Dilia Giuggioli10, Serena Guiducci1, Florenzo Iannone4, Francesca Ingegnoli11, Valeria Riccieri12, Marco Matucci Cerinic6-7, Clodoveo Ferri10-13, Silvia Bellando Randone1. | 1Division of Rheumatology, Scleroderma Unit, Department of Experimental and Clinical Medicine, University of Florence, AO, Firenze, Italy; 2Division of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland; 3Rheumatology Division, Catholic University of the Sacred Heart, Fondazione Policlinico Universitario A. Gemelli- IRCCS, Roma, Italy; 4Rheumatology Unit, Department of Precision and Regenerative Medicine-Ionian Area, University of Bari Aldo Moro, Bari, Italy; 5Reumatology Service, Internal Medicine Unit F.Miulli General Hospital, Acquaviva delle Fonti -Department of Medicine a, Bari, Italy; 6Unit of Immunology, Rheumatology, Allergy and Rare Diseases UnIRAR, Inflammation, Fibrosis and Ageing initiative INFL, Milano, Italy; 7Vita-Salute San Raffaele University, Milano, Italy; 8Department of Internal Medicine and Therapeutics, Università di Pavia, Italy; Division of Rheumatology, Fondazione IRCCS, Pavia, Italy; 9Rheumatology Unit, Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Ancona, Italy; 10Rheumatology Unit, School of Medicine, University of Modena and Reggio Emilia, Modena, Italy; 11Division of Clinical Rheumatology, ASST Pini, Dept. of Clinical Sciences and Community Health, Research Center for Adul, Milano, Italy; 12Department of Rheumatology, Sapienza University of Rome, Roma, Italy; 13Rheumatology Clinic Madonna dello Scoglio Crotonei, Crotone, Italy.
197 -
PO:31:165 | Prevalence and incidence of skin telangectasia and their association with clinical features: analysis of the European Scleroderma Trials and Research cohort Gemma Lepri1, Lorenzo Tofani2, Silvia Bellando Randone1, Veronica Batani3, Paolo Airò4, Patricia Carreira5, Joerg Henes6, Alexandra Balbir Gurman7, Florenzo Iannone8, Antonella Marcoccia9, Luc Mouthon10, Branimir Anic11, Carolina De Souza Müller12, Armine Haroyan13, Ana Cristina Cordeiro14, Serena Guiducci And Eustar Coll1. | 1University of Florence, Dept of Experimental and Clinical Medicine, AOU Careggi, Division of Rheumatology Florence Italy; 2University of Florence, Dept of Statistics, Informatics, Applications, Florence, Italy; 3Unit of Immunology, Rheumatology, Allergy and Rare Diseases UnIRAR, IRCCS San Raffaele, Milano, Italy; 4Scleroderma Unit, UOC Rheumatology and Clinical Immunology, ASST Spedali Civili, Brescia, Italy; 5Dept of Rheumatology, 12 de Octubre University Hospital, Madrid, Spain; 6Centre for Interdisciplinary Rheumatology, Immunology and autoimmune diseases INDIRA, University Hospital Tuebingen, Tuebingen, Germany; 7Rheumatology Institute, Rambam Health Care Campus Haifa Israel; 8Dept of Precision and Regenerative Medicine and Ionian Area, University of Bari, Bari, Italy; 9Interdisciplinary Reference Center for Systemic Sclerosis CRIIS Sandro Pertini Hospital, Rome, Italy; 10Dept of Internal Medicine, Cochin Hospital, Paris Cité University, Paris, France; 11Div Clinical Immunology and Rheumatology, Dept Internal Medicine, School of Medicine, University Hospital Center Zagreb, Zagreb, Croatia; 12Rheumatology Division, Hospital de Clínicas da Universidade Federal do Parana, Curitiba, Brazil; 13Dept of Rheumatology, Yerevan State Medical University of Armenia, Yerevan, Armenia; 14Servico Reumatologia Hospital Garcia de Orta Almada, Almada, Portugal.
190 -
PO:32:176 | Outcomes of upfront combination vs monotherapy with rituximab or mycophenolate mofetil for systemic sclerosis interstitial lung disease: results from a European Scleroderma Trials and Research cohort study Devis Benfaremo1, Corrado Campochiaro2, Gábor Kumánovics3, Christina Bergmann4, Elisabetta Zanatta5, David Launay6, Serena Guiducci7, Mickael Martin8, Carolina De Souza Müller9, Carlomaurizio Montecucco10, Luc Mouthon11, Gabriella Szucs12, Kastriot Kastrati13, Marie-Elise Truchetet14, Madelon Vonk15, Francesco Del Galdo16, Marco Matucci-Cerinic2, Gianluca Moroncini1, Yannick Allanore17. | 1Department of Clinical and Molecular Sciences, Marche Polytechnic University, Marche University Hospital, Ancona, Italy; 2Vita-Salute San Raffaele University, San Raffaele Hospital, Milano, Italy; 3University of Pécs, Department Of Rheumatology And Immunology, Pécs, Hungary; 4University Hospital Erlangen, Department Internal Medicine 3, Erlangen, Germany; 5Padova University Hospital, Rheumatology Unit, Padova, Italy; 6Univ. Lille, Inserm, CHU Lille, Department of Internal Medicine and Clinical Immunology, Lille, France; 7University of Florence, Azienda Ospedaliera Universitaria Careggi, Firenze, Italy; 8Poitiers University Hospital, Department of Internal Medicine Poitiers France; 9Hospital de Clinicas da Universidade Federal do Parana Curitiba Brazil; 10Università di Pavia e IRCCS Fondazione Policlinico S. Matteo, Pavia, Italy; 11Hôpital Cochin, Department of Internal Medicine, Paris, France; 12University of Debrecen, Faculty of Medicine, Department of Rheumatology, Debrecen, Hungary; 13Medical University of Vienna, Department of Medicine III, Division of Rheumatology, Vienna, Austria; 14CHU de Bordeaux, Rheumatology department, Bordeaux, France; 15Radboudumc, Department of Rheumatology Nijmegen The Netherlands; 16Leeds Raynauds and Scleroderma Program, NIHR Biomedical Research Centre, Leeds, United Kingdom; 17Université Paris Cité, Cochin Hospital, Rheumatology Department, Paris, France.
199 -
Real-life effectiveness of rituximab in different subsets of idiopathic inflammatory myopathies
2493PDF: 685SUPPLEMENTARY MATERIAL: 355
